ICU Medical Receives a Hold from Roth Capital

By Carrie Williams

In a report released today, Chris Lewis from Roth Capital reiterated a Hold rating on ICU Medical (NASDAQ: ICUI), with a price target of $172. The company’s shares opened today at $169, close to its 52-week high of $175.73.

According to, Lewis is a 4-star analyst with an average return of 7.0% and a 50.8% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Cogentix Medical Inc, Trinity Biotech Plc, and Lemaitre Vascular.

ICU Medical has an analyst consensus of Moderate Buy, with a price target consensus of $171.

The company has a one year high of $175.73 and a one year low of $98.15. Currently, ICU Medical has an average volume of 122.8K.

Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ICUI in relation to earlier this year. Most recently, in March 2017, George Lopez, a Director at ICUI bought 12,000 shares for a total of $1,867,200.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ICU Medical, Inc. develops, manufactures and sells medical devices used in infusion therapy, oncology and critical care applications. It operates through the following segments: Infusion Therapy, Critical Care, and Oncology. The Infusion Therapy segment provides needlefree connector products, custom infusion sets, and Tego, a neddlefree hemodialysis connector. The Critical Care segment offers: hemodynamic monitoring systems; closed blood sampling and conservation systems; and other critical care products and accessories. The Oncology segment sells ChemoLock CSTD and components; ChemoClave CSTD and components; and Diana hazardous drug compounding systems. The company was founded by George A. Lopez in 1984 and is headquartered in San Clemente, CA.